Search Results
Search for other papers by Jiahui Wu in
Google Scholar
PubMed
Search for other papers by Xunyang Hu in
Google Scholar
PubMed
Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Search for other papers by Paula Seal in
Google Scholar
PubMed
Search for other papers by Parthiv Amin in
Google Scholar
PubMed
Mayfair Radiology, Calgary, Alberta, Canada
Search for other papers by Brendan Diederichs in
Google Scholar
PubMed
Departments of Medicine, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
. and Grani et al. ( 5 , 6 ). In 2013, the European Thyroid Association (ETA) released POU guidelines for patients with thyroid cancer, which defined POU criteria for lymph node and thyroid bed nodule assessment ( 7 ). A retrospective assessment of
Search for other papers by Luigino Dal Maso in
Google Scholar
PubMed
Search for other papers by Daniela Pierannunzio in
Google Scholar
PubMed
Search for other papers by Silvia Francisci in
Google Scholar
PubMed
Search for other papers by Angela De Paoli in
Google Scholar
PubMed
Search for other papers by Federica Toffolutti in
Google Scholar
PubMed
Search for other papers by Salvatore Vaccarella in
Google Scholar
PubMed
Search for other papers by Silvia Franceschi in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Ugo Fedeli in
Google Scholar
PubMed
Search for other papers by of the DEPTH Working Group in
Google Scholar
PubMed
Nuclear Medicine Department to perform this treatment. Beginning with the 2006 American Thyroid Association (ATA) guidelines, which were updated in 2009 and 2015, more selective use of RAI has been recommended ( 5 , 6 , 7 ). In 2009, RAI ablation was
Search for other papers by Furio Pacini in
Google Scholar
PubMed
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Daria Handkiewicz-Junak in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Johannes W Smit in
Google Scholar
PubMed
-8587(1830113-X ) 8 Haugen BR Alexander EK Bible KC Doherty GM Mandel SJ Nikiforov YE Pacini F Randolph GW Sawka AM Schlumberger M 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Lea Contartese in
Google Scholar
PubMed
Search for other papers by Liborio Torregrossa in
Google Scholar
PubMed
Search for other papers by Francesca Bianchi in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Gabriele Materazzi in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
the disease is detected during the follow-up. According to the suggestions of the most recent ATA 2015 guidelines ( 1 ), the risk of recurrence should be redefined at each clinical control according to clinical, biochemical, and imaging evaluations. If
Search for other papers by Grace Segall in
Google Scholar
PubMed
Search for other papers by Ravinder Singh in
Google Scholar
PubMed
Search for other papers by Min-Hua Jen in
Google Scholar
PubMed
Search for other papers by Isaac Sanderson in
Google Scholar
PubMed
Search for other papers by Alex Rider in
Google Scholar
PubMed
Search for other papers by Katie Lewis in
Google Scholar
PubMed
Search for other papers by Urpo Kiiskinen in
Google Scholar
PubMed
). Germline RET mutations are present in up to 10% of patients with apparently sporadic MTCs ( 5 , 10 ). European Society for Medical Oncology (ESMO) guidelines recommend that screening for RET mutations should be strongly considered in all patients with
Search for other papers by Andrea Leoncini in
Google Scholar
PubMed
Search for other papers by Chiara Camponovo in
Google Scholar
PubMed
Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
Search for other papers by Gaetano Paone in
Google Scholar
PubMed
Search for other papers by Elena Gamarra in
Google Scholar
PubMed
Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
Search for other papers by Giorgio Treglia in
Google Scholar
PubMed
Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
Search for other papers by Pierpaolo Trimboli in
Google Scholar
PubMed
still recognized as the gold standard for detecting AFTN, authors suggested integrating TS in the TIRADS model to prevent UN-FNACs ( 10 , 12 , 13 ). However, the TIRADS-based strategy was proven highly accurate and guidelines recommend TS only in TN
Search for other papers by Marine Sitbon in
Google Scholar
PubMed
Search for other papers by Porhuoy Chou in
Google Scholar
PubMed
Search for other papers by Seydou Bengaly in
Google Scholar
PubMed
Search for other papers by Brigitte Poirot in
Google Scholar
PubMed
Search for other papers by Marie Laloi-Michelin in
Google Scholar
PubMed
Search for other papers by Laure Deville in
Google Scholar
PubMed
Search for other papers by Atanas Pachev in
Google Scholar
PubMed
Search for other papers by Ahouefa Kowo-Bille in
Google Scholar
PubMed
Search for other papers by Clement Dumont in
Google Scholar
PubMed
Search for other papers by Cécile N Chougnet in
Google Scholar
PubMed
illustrates response to selpercatinib in vandetanib-naïve patients. The latest MTC guidelines suggest the benefit of molecular testing in all MTC cases ( 16 ), paving the way toward upfront-targeted treatment with RET-targeted agents. In addition, our case
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Desiree’ Deandreis in
Google Scholar
PubMed
Search for other papers by Cosimo Durante in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Romana Netea-Maier in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Susanne Singer in
Google Scholar
PubMed
Search for other papers by Gerasimos P Sykiotis in
Google Scholar
PubMed
Search for other papers by Beate Bartes in
Google Scholar
PubMed
Search for other papers by Kate Farnell in
Google Scholar
PubMed
Department of Internal Medicine and Therapeutics, University of Pavia, Italy
Search for other papers by Laura Deborah Locati in
Google Scholar
PubMed
, location of metastases, and clinical status ( 8 ). A number of societies have issued guidance for the initiation of MKIs; however, their recommendations are not totally uniform. For example, the National Comprehensive Cancer Network guidelines recommend
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed
Nova Medical School, Lisbon, Portugal
Search for other papers by Sara Donato in
Google Scholar
PubMed
Search for other papers by Mariana Horta in
Google Scholar
PubMed
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Search for other papers by Miguel Rito in
Google Scholar
PubMed
Search for other papers by Pedro Gomes in
Google Scholar
PubMed
Nova Medical School, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
represent a molecular target for cancer therapy, and the current American Thyroid Association (ATA) ( 4 ) ATC guidelines recommend analysis of somatic fusions in tumors without other candidate driver genes, such as BRAF. Currently, there are two drugs
University of Lille, Lille, France
Search for other papers by Benjamin Chevalier in
Google Scholar
PubMed
Search for other papers by Oriane Karleskind in
Google Scholar
PubMed
University of Lille, Lille, France
Search for other papers by Arnaud Jannin in
Google Scholar
PubMed
Search for other papers by Olivier Farchi in
Google Scholar
PubMed
Search for other papers by Catherine Vermaut in
Google Scholar
PubMed
CRIStAL UMR CNRS 9189, University of Lille, Villeneuve-d’Ascq, France
Search for other papers by Alexandre Escande in
Google Scholar
PubMed
Search for other papers by Clio Baillet in
Google Scholar
PubMed
University of Lille, Lille, France
Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes (EGID), CHU Lille, Lille, France
Search for other papers by Stéphanie Espiard in
Google Scholar
PubMed
University of Lille, Lille, France
Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes (EGID), CHU Lille, Lille, France
Search for other papers by Marie-Christine Vantyghem in
Google Scholar
PubMed
Search for other papers by Bruno Carnaille in
Google Scholar
PubMed
Department of Pathology, Lille University Hospital, Lille, France
University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
Search for other papers by Emmanuelle Leteurtre in
Google Scholar
PubMed
Search for other papers by Christine Do Cao in
Google Scholar
PubMed
(full list available in supplemental data) revealed a likely pathogenic variant (Class 4 according to the ACMG guidelines for the interpretation of sequence variants) in ATM (c.1123 A>T, p.(Arg375*)), resulting in an early stop codon ( 5 ). A variant